response-2: 5-year follow-up of second-line ruxolitinib therapy for pv
Published 3 years ago • 79 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
4:42
response-2 trial: ruxolitinib for pv
-
2:49
the 5-year update on the comfort-ii clinical trial of ruxolitinib
-
1:46
results for the follow-up of the response study
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
1:30
the patient perspective of polycythemia vera and second-line treatment options
-
1:05:02
part 2: introduction to fhir
-
6:49
the efficacy and safety of hydroxyurea therapy vs.switching to ruxolitinib in pv patients
-
1:53
jakavi
-
3:34
a response to ruxolitinib: update on 4-year trial follow-up
-
3:07
further analysis of response trial data validates ruxolitinib as second-line therapy
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
2:38
ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
-
5:50
case 2: the response trial of ruxolitinib for pv
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:02
conti-pv: a 2-year follow-up of interferon product aop2014
-
5:05
comfort-ii clinical trial: the 5 yr results
-
2:36
phase ii study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
-
3:37
2 year dfs data from the captivate trial
-
1:51
results for trial of lcl161 for pmf, post-pv mf, and post-et mf patients
-
5:24
krt‑232: first-in-class mdm2i for myelofibrosis r/r to jak inhibitor therapy
-
2:16
late effects of hsct in young patients with all: transition to adult services & long-term follow-up